VACCINE FOR CERVICAL CANCER

摘要

The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix „¢ and Gardasil „¢ , exhibiting a superior efficacy as a vaccine for a human cervical cancer.